Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of Peripheral Blood CHI3L1 for Tumor Radiosensitivity: A Prospective and Retrospective Cohort Study

NCT07071688 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT07071688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07071688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of Peripheral Blood CHI3L1 for Tumor Radiosensitivity: A Prospective and Retrospective Cohort Study
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Observational
Overall status
Not yet recruiting
Start date
July 20, 2025
Completion date
December 31, 2028
Enrollment
338 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

biomarker, radiotherapy, tumor